What do systematic reviews say?

Vaginal hysterectomy vs sacral hysteropexy/cervicopexy (uterine prolapse)

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 422 participants
  Very low

Vaginal hysterectomy vs sacral hysteropexy/cervicopexy (uterine prolapse)

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 148 participants
  Low

Vaginal hysteropexy vs sacral hysteropexy (uterine prolapse)

Vaginal hysteropexy showed no clear difference in awareness of prolapse compared with sacral hysteropexy (uterine prolapse) (low certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 0.55 [0.21, 1.44]
  1 study · 257 participants
  Low

Vaginal hysteropexy vs sacral hysteropexy (uterine prolapse)

Vaginal hysteropexy showed no clear difference in surgery for recurrent prolapse compared with sacral hysteropexy (uterine prolapse) (moderate certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 1.34 [0.52, 3.44]
  2 studies · 345 participants
  Moderate

Vaginal hysteropexy vs sacral hysteropexy (uterine prolapse)

Vaginal hysteropexy showed no clear difference in prolapse on examination (Stage 2 or above) ‐ Any recurrent prolapse compared with sacral hysteropexy (uterine prolapse) (moderate certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 0.99 [0.83, 1.19]
  2 studies · 367 participants
  Moderate

Vaginal hysteropexy vs sacral hysteropexy (uterine prolapse)

It is very uncertain whether vaginal hysteropexy changes mesh exposure (1‐4 years) compared with sacral hysteropexy (uterine prolapse) (very low certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 7.05 [0.37, 135.2]
  1 study · 257 participants
  Very low

Vaginal procedure vs sacral colpopexy (vault prolapse)

Vaginal procedure probably leads to higher surgery for recurrent prolapse compared with sacral colpopexy (vault prolapse) (moderate certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 2.33 [1.34, 4.04]
  6 studies · 497 participants
  Moderate

Vaginal hysteropexy vs sacral hysteropexy (uterine prolapse)

Vaginal hysteropexy showed no clear difference in painful intercourse ‐ De novo dyspareunia compared with sacral hysteropexy (uterine prolapse) (moderate certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 1.86 [0.72, 4.83]
  2 studies · 203 participants
  Moderate

Vaginal hysteropexy vs sacral hysteropexy (uterine prolapse)

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 209 participants
  Low

Vaginal procedure vs sacral colpopexy (vault prolapse)

Vaginal procedure probably leads to higher prolapse on examination (Stage 2 or above) ‐ Any recurrent prolapse compared with sacral colpopexy (vault prolapse) (moderate certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 1.87 [1.32, 2.65]
  5 studies · 422 participants
  Moderate

Vaginal procedure vs sacral colpopexy (vault prolapse)

Vaginal procedure showed no clear difference in intraoperative Visceral injury compared with sacral colpopexy (vault prolapse) (moderate certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 0.46 [0.13, 1.63]
  7 studies · 625 participants
  Moderate

Vaginal procedure vs sacral colpopexy (vault prolapse)

Vaginal procedure probably leads to higher bladder Function ‐ Stress incontinence compared with sacral colpopexy (vault prolapse) (moderate certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 1.86 [1.17, 2.94]
  3 studies · 263 participants
  Moderate

Vaginal procedure vs sacral colpopexy (vault prolapse)

Vaginal procedure showed no clear difference in painful intercourse ‐ Dyspareunia compared with sacral colpopexy (vault prolapse) (low certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 3.44 [0.61, 19.53]
  3 studies · 106 participants
  Low

Vaginal procedure vs sacral colpopexy (vault prolapse)

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 517 participants
  Low

Vaginal procedure vs sacral colpopexy (vault prolapse)

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 188 participants
  Low

Vaginal hysterectomy vs sacral hysteropexy/cervicopexy (uterine prolapse)

It is very uncertain whether vaginal hysterectomy changes awareness of prolapse compared with sacral hysteropexy/cervicopexy (uterine prolapse) (very low certainty).

• Surgery for women with apical vaginal prolapse 2023 · Cochrane Headline outcomes only
  RR 1.01 [0.1, 9.98]
  2 studies · 200 participants
  Very low

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

The review found no eligible studies for this question.

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.5 [2.13, 2.94]
  14 studies · 7988 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.1 [1.84, 2.4]
  6 studies · 2629 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.23 [1.49, 3.34]
  1 study · 343 participants
  Very low